Pharmacokinetically Guided Administration of Chemotherapeutic Agents

Prediction of Creatinine Clearance from Serum Creatinine

1976 • 15,066 citations

Bone marrow transplant

1997 • 3,583 citations

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

1989 • 1,831 citations

Serum Creatinine as an Index of Renal Function: New Insights into Old Concepts

1992 • 1,549 citations

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

1995 • 550 citations

Creatinine Clearance: Bedside Estimate

1973 • 489 citations

Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia

1998 • 487 citations

Phase I clinical and pharmacokinetic study of taxol.

1987 • 449 citations

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1998 • 420 citations

Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

1989 • 408 citations

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1977 • 390 citations

Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia

1986 • 380 citations

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.

1992 • 369 citations

Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function

1995 • 359 citations

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

1996 • 353 citations

Optimal sampling times for pharmacokinetic experiments

1981 • 324 citations

Association of busulfan area under the curve with veno-occlusive disease following BMT.

1996 • 318 citations

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

1993 • 311 citations

Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.

1984 • 304 citations

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

1995 • 302 citations

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

1994 • 249 citations

Clinical Pharmacokinetics of Carboplatin

1991 • 247 citations

Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient Characteristics

1995 • 243 citations

Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.

1993 • 218 citations

Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

1987 • 216 citations

Patient characteristics associated with high-risk methotrexate concentrations and toxicity.

1994 • 212 citations

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.

1996 • 206 citations

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1996 • 204 citations

Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response.

1992 • 193 citations

Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

1985 • 190 citations

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

1989 • 190 citations

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

1997 • 181 citations

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1989 • 173 citations

Relationship between fluorouracil systemic exposure and tumor response and patient survival.

1994 • 158 citations

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.

1998 • 156 citations

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

1996 • 156 citations

Clinical Pharmacokinetics and Dose Optimisation of Carboplatin

1997 • 153 citations

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

1996 • 147 citations

A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer

1994 • 139 citations

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

1994 • 139 citations

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

1997 • 138 citations

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.

1994 • 138 citations

Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity.

1987 • 138 citations

Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.

1998 • 136 citations

Pharmacodynamics in cancer therapy.

1990 • 135 citations

Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.

1988 • 131 citations

The Use of Population Pharmacokinetics in Drug Development

1996 • 131 citations

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.

1997 • 125 citations

Pharmacokinetics of anticancer agents in patients with impaired liver function

1998 • 116 citations

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.

1987 • 115 citations

Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.

1983 • 113 citations

High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.

1987 • 112 citations

Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose

1988 • 111 citations

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.

1991 • 110 citations

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

1986 • 110 citations

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

1998 • 110 citations

Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.

1982 • 110 citations

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation

1995 • 103 citations

Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors.

1991 • 103 citations

Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer

1999 • 102 citations

Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.

1990 • 100 citations

The measurement of cisplatin-DNA adduct levels in testicular cancer patients

1988 • 98 citations

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.

1994 • 97 citations

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1995 • 95 citations

Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability

1989 • 94 citations

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.

1991 • 91 citations

Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin

1989 • 90 citations

Practical Treatment Guide for Dose Individualisation in Cancer Chemotherapy

1998 • 90 citations

Combination chemotherapy studies with gemcitabine.

1997 • 89 citations

Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients

1996 • 87 citations

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

1994 • 86 citations

Platinum—DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry

1991 • 84 citations

Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.

1990 • 83 citations

Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation

1992 • 82 citations

Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.

1987 • 80 citations

Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation

1992 • 80 citations

Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin

1987 • 77 citations

Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

1987 • 77 citations

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

1997 • 75 citations

Dose Versus pharmacokinetics for predicting tolerance to 5‐day continuous infusion of 5‐FU

1988 • 73 citations

Pharmacology and Clinical Toxicity of 4'-Iodo-4'-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials

1990 • 73 citations

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases

1988 • 72 citations

A limited sampling strategy for cyclophosphamide pharmacokinetics.

1989 • 70 citations

Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer

1999 • 69 citations

A limited sampling method for estimation of the carboplatin area under the curve

1993 • 66 citations

A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics

1998 • 66 citations

Limited-sampling models for anticancer agents

1994 • 65 citations

Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.

1986 • 61 citations

High-dose methotrexate: Preliminary evaluation of a pharmacokinetic approach

1979 • 61 citations

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement

1991 • 59 citations

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.

1996 • 56 citations

Clinical pharmacodynamics of continuous-infusion etoposide

1990 • 56 citations

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin

1995 • 54 citations

Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.

1995 • 54 citations

The use of the Calvert formula to determine the optimal carboplatin dosage

1995 • 53 citations

Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods

2000 • 53 citations

Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing

1997 • 52 citations

A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.

1997 • 50 citations

Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.

1993 • 48 citations

Individual dose adaptation of anticancer drugs

1994 • 48 citations

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide

1997 • 47 citations

Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.

1996 • 47 citations

A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve

1996 • 47 citations

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer

1997 • 45 citations

Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients

1991 • 45 citations

Modeling Interpatient Pharmacodynamic Variability of Etoposide

1991 • 43 citations

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

1989 • 42 citations

Phase I Trial of Granulocyte--Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 Weeks: a Cancer and Leukemia Group B Study

1993 • 42 citations

The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis

1992 • 41 citations

Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin

1987 • 41 citations

Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae

1998 • 41 citations

Phase I and pharmacological study of vinblastine by prolonged continuous infusion.

1986 • 39 citations

Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.

1986 • 38 citations

Dose optimisation of carboplatin in adults.

1994 • 38 citations

Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.

1998 • 38 citations

Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs

1982 • 37 citations

Overview of recent topics in clinical pharmacology of anticancer agents

1998 • 37 citations

Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.

1993 • 36 citations

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

1996 • 36 citations

Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer

1997 • 36 citations

A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide.

1989 • 36 citations

Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring.

1993 • 33 citations

Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors*

1995 • 33 citations

Dose optimization of carboplatin in adults

1994 • 31 citations

Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.

1996 • 30 citations

Pharmacokinetics of paclitaxel and carboplatin in combination.

1995 • 30 citations

Pharmacokinetics and cancer chemotherapy

1994 • 30 citations

Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer

1992 • 29 citations

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

1998 • 28 citations

A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children

1998 • 28 citations

A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer

1999 • 28 citations

Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.

1987 • 28 citations

Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.

1993 • 27 citations

Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects

1989 • 27 citations

A sequential Bayesian algorithm for dose individualisation of carboplatin

1997 • 26 citations

Limited sampling models for topotecan pharmacokinetics

1994 • 25 citations

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours

1990 • 25 citations

A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.

1995 • 25 citations

Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination

1994 • 24 citations

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels

1999 • 24 citations

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.

1992 • 24 citations

Renal handling of carboplatin

1992 • 24 citations

Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.

1987 • 24 citations

High-dose methotrexate: A clinical and pharmacokinetic evaluation

1982 • 23 citations

Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.

1997 • 22 citations

Approaches to optimal dosing of hexamethylene bisacetamide

1992 • 21 citations

Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer.

1999 • 20 citations

A Bayesian dosing method for carboplatin given by continuous infusion for 120 h

1997 • 20 citations

Clinical pharmacological evaluation of CPT-11 and cisplatin (CDDP) in patients with small cell lung cancer (SCLC)

1995 • 20 citations

Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.

1994 • 20 citations

Carboplatin dose in combination chemotherapy for testicular cancer

1991 • 19 citations

A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer

1995 • 17 citations

A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941

1996 • 17 citations

Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study

1995 • 15 citations

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen

1999 • 14 citations

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel

1999 • 14 citations

High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours

1993 • 13 citations

Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.

1992 • 13 citations

Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer.

1996 • 12 citations

A Limited Sampling Model with Bayesian Estimation to Determine Inulin Pharmacokinetics Using the Population Data Modelling Program P-PHARM

1995 • 12 citations

Phase II studies of 4’-iodo-4’-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers

1991 • 12 citations

Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model

1998 • 11 citations

Revisiting Some Factors Contributing to Variability

1992 • 11 citations

Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide

1990 • 10 citations

Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.

1986 • 9 citations

Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia

1991 • 9 citations

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.

1997 • 9 citations

Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days

1988 • 8 citations

Is creatinine clearance a sufficient measurement for GFR in carboplatin dose calculation?

1993 • 7 citations

Phase II study of 4?-iodo-4?-deoxydoxorubicin in non-resectable non-small-cell lung cancer

1993 • 6 citations

Pharmacokinetic modelling—A prelude to therapeutic drug monitoring for all cancer patients?

1995 • 6 citations

926 Pharmacokinetics (PK), clinical pharmacodynamics (PD) and safety of chronic oral topotecan (T), in a phase I study

1995 • 5 citations

Deleted Work

1955 • 0 citations